Cargando…
An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases
The critical role of IgE in allergic diseases is well-documented and clinically proven. Omalizumab, a humanized anti-IgE antibody, was the first approved antibody for the treatment of allergic diseases. Nevertheless, omalizumab still has some limitations, such as product instability and dosage restr...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728613/ https://www.ncbi.nlm.nih.gov/pubmed/33329588 http://dx.doi.org/10.3389/fimmu.2020.596908 |